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From the Midwestern Vascular Surgical Society

Incidence and prognosis of vascular complications
after percutaneous placement of left ventricular
assist device
Miriam Abaunza, MD,a Loay S. Kabbani, MD,a Timothy Nypaver, MD,a Adam Greenbaum, MD,b
Praveen Balraj, MD,a Sherazuddin Qureshi, MD,a Mohammed A. Alqarqaz, MD,b and
Alexander D. Shepard, MD,a Detroit, Mich
Objective: Mechanical assist devices have found an increasingly important role in high-risk interventional cardiac procedures. The Impella (Abiomed Inc, Danvers, Mass) is a percutaneous left ventricular assist device inserted through the
femoral artery under ﬂuoroscopic guidance and positioned in the left ventricular cavity. This study was undertaken to assess
the incidence of vascular complications and associated morbidity and mortality that can occur with Impella placement.
Methods: We used a prospective database to review patients who underwent placement of an Impella left ventricular assist
device in our tertiary referral center from July 2010 to December 2013. Patient demographics, comorbidities, interventional complications, and 30-day mortality were recorded.
Results: The study included 90 patients (60% male). Mean age was 66 years (range, 17-97 years). Hypertension was found in
69% of the patients, 37% were diabetic, 57% had a history of tobacco abuse, and 65% had chronic renal insufﬁciency. The median
preprocedure cardiac ejection fraction was 30%. Most (87%) had undergone coronary artery intervention. Cardiogenic shock
was documented in 67 patients (74%). The Impella was placed for an average of 1 day (range, 0-5 days). At least one vascular
complication occurred in 15 patients (17%). Acute limb ischemia occurred in 12 patients; of whom four required an amputation
and six required open or endovascular surgery. Other complications included groin hematomas and one pseudoaneurysm. Allpatient 30-day mortality was 50%, which was not signiﬁcantly associated with vascular complications. Female sex and
cardiogenic shock at the time of insertion were associated with vascular complications (P [ .043 and P [ .018, respectfully).
Conclusions: Vascular complications are common with placement of the Impella percutaneous left ventricular assist
device (17%) and are related to emergency procedures. Vascular complications in this high-risk patient population
frequently lead to withdrawal of care. These data provide quality improvement targets for left ventricular assist device
programs. (J Vasc Surg 2015;62:417-23.)

The evolution of left ventricular (LV) assist devices
(LVADs) into percutaneous devices has helped advance
the boundaries of interventional cardiology in the past
decade. Percutaneous LVADs (P-LVADs) have found
two major applications. The ﬁrst is the provision of active
circulatory support for patients in cardiogenic shock
(CS).1-4 The second application pertains to elective highrisk percutaneous cardiac interventional procedures (eg,
stenting a tight left main stenosis), where periprocedural
P-LVAD support is thought to decrease the incidence of
adverse events.5
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The Impella system (Abiomed Inc, Danvers, Mass) is a
minimally invasive P-LVAD that is placed in a retrograde
fashion across the aortic valve via the femoral artery by
applying conventional catheterization techniques. A miniaturized rotary pump is used to draw blood from the LV
cavity and expel it into the ascending aorta, providing
2.5 L/min to 5 L/min forward ﬂow, depending on the
device used.6 The 2.5 L/min device is placed through a
13F sheath. The Impella has been used for cardiac support
in CS patients and in patients undergoing high-risk interventional procedures.
Initial studies indicated a low incidence of vascular
complications with the use of the Impella device, despite
the multiple risk factors for development of vascular complications associated with the use of such a device,
including large sheath size, low cardiac output state, and
frequent presence of peripheral vascular disease (PAD).6-8
The goal of this study was to analyze our experience with
the Impella device, with special focus on vascular complications and their relation to morbidity and mortality.
METHODS
This study was approved by the Henry Ford Hospital
Institutional Review Board and was conducted in accordance with the Health Insurance Portability and
417
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Table I. Circumstances surrounding Impellaa placement

Variable
Elective (planned)
Urgent (preprocedure CS)
Emergent (intraprocedure CS)

No VC
(n ¼ 75),
No. (%)

VC
(n ¼ 15),
No. (%)

23 (31)
32 (43)
20 (27)

0 (0)
7 (21)
8 (40)

Table II. Demographic and comorbidity descriptive
statistics, stratiﬁed by vascular complications
Vascular complications

P value
.02

CS, Cardiogenic shock.
a
Abiomed Inc, Danvers, Mass.

Accountability Act and the prevailing ethical principles
governing research.
Identiﬁcation of patients. A retrospective record
review was undertaken of a prospectively maintained database on all Impella implantations at a single institution.
Patient informed consent was waived.
Data collection and study end points. We reviewed
the outcomes of 98 Impella P-LVAD devices placed at
our institution between July 2010 and December 2013.
Data were obtained from a prospectively maintained catheterization laboratory database and from the electronic
medical records. Collected data included demographics,
comorbidities, procedure-related characteristics, vascular
complications, and 30-day mortality.
Vessel size was determined by calibrating the common
femoral artery (CFA) diameter on the procedural angiogram
to the catheter and sheath size. CS was deﬁned using clinical
and hemodynamic criteria, as previously described in the
Should We Emergently Revascularize Occluded Coronaries
for Cardiogenic Shock (SHOCK) trial.9 Vascular complications were conﬁrmed based on the interventions performed,
or when medical management was undertaken, on ﬁndings
documented in the medical record. The nature of the
complication was determined by details contained within
the operative or consultation notes.
The Impella device. The Impella is an intracardiac
miniaturized rotary pump P-LVAD. This cathetermounted continuous-ﬂow axial pump is placed across the
aortic valve under ﬂuoroscopic guidance with inﬂow in the
LV and outﬂow in the ascending aorta. The Impella provides hemodynamic support by unloading the LV and
augmenting forward ﬂow.10 The device decreases
myocardial workload while increasing cardiac output and
end-organ perfusion. Placement of the device is indicated
in patients with reduced LV function after coronary bypass
and for support during high-risk percutaneous coronary
interventions.11,12 The size of the pump catheter can be as
small as 12F, which is placed through a 13F sheath. The
family of Impella catheters includes, in ascending order for
size and ﬂow: Impella 2.5 (12F, 2.5 L/min of ﬂow),
Impella Continuous Power (14F, 3.5 L/min of ﬂow),
Impella 5.0 (21F, 5 L/min of ﬂow), and Impella Left
Direct (21F, 5 L/min of ﬂow). Although the Impella 2.5
and Continuous Power are percutaneous devices that ﬁt
through 13F and 14F sheaths, respectively, the Impella 5.0
and Left Direct catheters are usually placed after surgical

Variablea

No (n ¼ 75) Yes (n ¼ 15) P valueb

Demographic
Sex
Female
26 (35)
10 (67)
Male
49 (65)
5 (33)
Age, years
67 6 15
58 6 20
Height, cm
171 6 11
167 6 10
Weight, kg
90 6 30
81 6 23
2
30 6 8
28 6 8
Body mass index, kg/m
2
2.0 6 0.33 1.9 6 0.29
Body surface area, m
Comorbidity
Hypertension
51 (68)
11 (73)
CVA
14 (19)
2 (13)
Hypothyroid
13 (17)
1 (6.7)
CHF
29 (39)
4 (27)
CAD
41 (55)
9 (60)
CABG
8 (11)
2 (13)
History of MI
18 (24)
2 (13)
COPD
7 (9.3)
3 (20)
Atrial ﬁbrillation
13 (17)
1 (6.6)
Diabetes mellitus
31 (41)
3 (20)
Hyperlipidemia
57 (76)
9 (60)
History of tobacco abuse
44 (60)
7 (47)
Current smoker
16 (22)
5 (33)
Cardiac arrest arrhythmia 11 (15)
3 (20)

.04
.14
.22
.23
.49
.21
.92
.90
.52
.56
.92
>.99
.57
.45
.51
.21
.34
.53
.52
.80

CABG, Coronary artery bypass grafting; CAD, coronary artery disease;
CHF, congestive heart failure; COPD, chronic obstructive pulmonary
disease; CVA, cerebrovascular accident; MI, myocardial infarction.
a
Categoric variables are presented as number (%) and continuous variables as
mean 6 standard deviation.
b
Continuous variables were tested using a two-sample t-test. Categoric
variables were tested with the Pearson c2 test, Fisher exact test, and by
logistic regression. Signiﬁcant P values are bolded.

exposure of the femoral artery because of their 21F catheter size. The Left Direct version has been used mainly for
patients after cardiac surgery.7 We did not place Impella
5.0 or Left Direct catheters during the study period.
Procedure. A transfemoral approach was used in most
patients to place the Impella device. Retrograde cannulation of the CFA was achieved via the standard Seldinger
technique, all placed by an interventional cardiologist.
Vascular femoral access was performed under ﬂuoroscopic
guidance; subsequently, a femoral angiogram through a
small-sized sheath was obtained, and if the puncture was
appropriate (ie, in the common femoral artery) and the
femoral artery on that side was adequate in size and free of
signiﬁcant disease, then that access site was used for
Impella insertion. Otherwise, a contralateral femoral
angiogram was performed ﬁrst via a diagnostic catheter
inserted from the ﬁrst access site, and access was obtained
on the other side under ﬂuoroscopic guidance. Ultrasound
imaging was not used here because the interventional
cardiologists at our facility are more comfortable with
ﬂuoroscopic guidance.
The vessel was then sequentially predilated using 8F,
10F, and 12F dilators. Subsequently, a 13F sheath for
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Table III. Outcomes of patients with vascular complications
Patient

Vascular complication

1
2
3
4
5
6

Hematoma
Hematoma
Acute limb ischemia
Acute limb ischemia
Acute limb ischemia
Pseudoaneurysm

7
8
9
10
11
12
13
14
15

Acute
Acute
Acute
Acute
Acute
Acute
Acute
Acute
Acute

limb
limb
limb
limb
limb
limb
limb
limb
limb

ischemia
ischemia
ischemia
ischemia
ischemia
ischemia
ischemia
ischemia
ischemia

Intervention

Hospital outcome

Compression device
Held pressure
Remove Impellaa
Remove Impella
Above-knee amputation
Patient unstable for open repair, placed
covered stent over pseudoaneurysm
Open repair and fasciotomy
Fasciotomy
Above knee amputation
Open repair
Mechanical thrombolysis
Death prior to open repair
Mechanical thrombolysis
Delayed amputation
Remove Impella

Alive at discharge
Hospice
Alive at discharge
Withdrawal of care
Withdrawal of care
Withdrawal of care
Withdrawal of care
Withdrawal of care
Alive at discharge
Alive at discharge
Alive at discharge
Cardiac arrest
Cardiac arrest
Cardiac arrest
Alive at discharge

a

Abiomed Inc, Danvers, Mass.

the Impella 2.5 or a 14F sheath for the Impella Continuous
Power was inserted into the artery. The device was
advanced in a retrograde fashion past the aortic valve under
ﬂuoroscopic guidance. The device provides circulatory support by pumping blood at a rate of 2.5 L/min for the
Impella 2.5 and 3.5 L/min for the Impella Continuous
Flow. Patients were fully anticoagulated with intravenous
unfractionated heparin while the device was in place. In
the catheterization laboratory the goal was to maintain an
activated clotting time of >250 seconds, and in the intensive care unit, using a preset heparin protocol, the goal was
to maintain an activated partial thromboplastin time at
twice the normal value (partial thromboplastin time of 60
to 80 seconds).
The procedure was categorized as “emergent” if the
patient needed P-LVAD support due to acute deterioration
during an interventional cardiac procedure, as “urgent” if
the patient was in CS before the procedure, and as “elective” if the Impella was placed prophylactically before a
planned high-risk procedure.
No computed tomography scans were obtained before
emergent and urgent procedures. In elective cases that
were performed in our facility, almost all patients had a
prior diagnostic coronary angiography with femoral artery
angiography and were subsequently scheduled to undergo
a high-risk coronary intervention with Impella support in a
separate procedure.
When a closure devise was used, two Perclose ProGlide
suture-mediated closure systems (Abbott Vascular, Redwood City, Calif) were deployed in the artery after obtaining access with a 6F sheath and before placement of the
Impella. The Perclose device was deployed (if the Impella
was taken out) or removed at the end of the case if the
Impella was left in given the risk of infection. When the
duration of Impella placement was thought to be
>1 day, the Perclose device was not used. Removal of
the device then was preformed after the activated clotting

time was <160 seconds, and hemostasis was achieved by
manual compression for at least 45 to 60 minutes by operators familiar and experienced in vascular access.
Limb ischemia was determined by presence of lower
extremity pain, paresthesia, or paralysis, if the patient was
awake and not ventilated. The physical examination typically consisted of a cool extremity, with absent Doppler signals in the dorsalis pedis and posterior tibial arteries. With
advanced ischemia, mottling of the skin was noted along
with muscle tenderness. Successful medical management
was achieved after the removal of the Impella device if
the signals in the dorsalis pedis or the posterior tibial arteries returned along with sensation and movement to
the affected leg and foot.
No clear algorithm was used to choose between intraaortic balloon pump (IABP) support and Impella placement in patients with CS. In severely hemodynamically
compromised patients, clinical experience would support
the higher hemodynamic support obtained from the
Impella, where even a patient with virtually no underlying
cardiac activity will still have a reasonable cardiac output of
2.5 to 3 L/min.
Data analysis. All patient data were compiled in a
spreadsheet. Proportions were compared with the Pearson
c2 test, Fisher exact test, and by logistic regression. Means
were compared using t-tests and analysis of variance. Analyses were done using SAS software (SAS Institute Inc,
Cary, NC). A P value of <.05 was considered statistically
signiﬁcant. For survival data, Kaplan-Meier analyses and
intergroup testing by log-rank testing was used.
RESULTS
Baseline and periprocedural characteristics.
Between July 2010 and December 2013, 98 Impella
devices were inserted in our interventional cardiology catheterization laboratory. Four patients underwent placement
of 2 Impella devices and were counted only once. Another
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Fig 1. Outcomes of patients with vascular complications.

Table IV. Indication for Impellaa placement

Variable
Primary reason for Impella
placement
Acute coronary syndrome
Balloon valvuloplasty or TAVR
Secondary diagnosis
Cardiac arrest/arrhythmia
CS
Presence of AV and/or
MV disease

No VC
VC
(n ¼ 75), (n ¼ 15),
No. (%)
No. (%) P value

66 (88)
9 (12)

12 (80)
3 (20)

.68
.09

11 (15)
37 (49)
11 (15)

3 (20)
13 (87)
8 (53)

.90
.02
.01

AV, Aortic valve; CS, cardiogenic shock; MV, mitral valve; TAVR, transcatheter aortic valve replacement; VC, vascular complication.
a
Abiomed Inc, Danvers, Mass.

4 patients underwent placement of a venous Impella device
and were excluded from our analysis. Of the 90 patients
who underwent Impella device placement via an arterial
access, 23 were stable patients who underwent elective
placement as prophylaxis for a high-risk cardiac procedure. In the other 67 patients the Impella was placed for
CS (Table I).
Patient demographics and comorbidities are noted in
Table II. The mean age was 66 6 16 years. There were
15 vascular complications: 1 pseudoaneurysm, 2 groin
hematomas, and 12 acute ischemic limbs. Of the acute
limb ischemia patients, ﬁve were treated medically and
seven with invasive intervention (their management
and outcomes are outlined in Table III and Fig 1).
Most Impella devices were removed on postprocedure
day 1 (median, 1 day; range 0-5 days). The time of Impella

removal was not correlated with vascular complications (P ¼
.5). Patients with CS had a longer duration of Impella device
placement (mean 0.8 6 0.25 days vs 1.9 6 0.24 days; P >
.001). The 30-day mortality was 48% for patients without
vascular complications and 57% for those with vascular complications (P ¼ .7).
Predictors of vascular complications. On univariate
analysis, female sex, CS, and a history of valve disease
were signiﬁcant factors associated with the development
of vascular complications (Tables I, IV, and V). Race,
smoking, diabetes, and pre-existing PAD were not
signiﬁcantly associated with vascular complications.
Although CFA size was not a signiﬁcant variable in
the development of vascular complications, for every 1mm decrease in vessel size, there was a 35% increase in
the odds of having a vascular complication (odds ratio,
1.35; 95% conﬁdence interval, 0.94-2.02; Fig 2). There
was no signiﬁcant association between the use of a
closure device and the development of vascular complications. No patient who underwent an elective high-risk
cardiac procedure had any vascular complications,
whereas vascular complications occurred in 21% of patients undergoing an urgent procedure and in 40% of
patients undergoing an emergent procedure (P ¼ .023;
Table I).
Thirty-day and long-term mortality. The occurrence of vascular complications did not signiﬁcantly affect
30-day or 1-year mortality rates (Fig 3). At 30 days, mortality was 48% for patients with no vascular complications
and 57% for those with vascular complications (P ¼ .7).
Patients who developed vascular complications had a
longer hospital stay (10 days vs 22 days; P ¼ .035) and
a trend toward “withdrawal of care” status (29% vs 60%;
P ¼ .12).
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Table V. Procedural variables during Impellaa placement
Variable
IABP, No. (%)
Inotropic support, No. (%)
CPR, No. (%)
Closure device, No. (%)
CFA, mean 6 SD mm

No VC (n ¼ 75)
26
36
17
17
5.7 6 1.5

(35)
(48)
(23)
(23)
(n ¼ 67)

VC (n ¼ 15)
5
12
5
2
5.0 6 1.9

(33)
(80)
(33)
(14)
(n ¼ 15)

P value
.99
.05
.58
.73
.18

CFA, common femoral artery; CPR, cardiopulmonary resuscitation; IABP, intra-aortic balloon support; SD, standard deviation; VC, vascular complication.
a
Abiomed Inc, Danvers, Mass.

Fig 2. The effect of vessel size on vascular complications.

DISCUSSION
CS occurs in 5% to 8% of patients hospitalized with
ST-elevation myocardial infarction.13 Despite aggressive
treatment and early revascularization, mortality with CS
can run as high as 50% to 70%.9 After successful revascularization, the stunned myocardium may require several days
to recover. A low cardiac output state may persist during
this period, leading to end-organ dysfunction and the
potential for early death. Mechanical circulatory support
during this time has been advocated to decrease mortality.14
In patients undergoing a high-risk percutaneous coronary
intervention, even brief episodes of myocardial ischemia
may result in hypotension and decreased cardiac output,
leading to a vicious cycle of coronary hypoperfusion, heart
failure, and hemodynamic collapse. Accordingly, prophylactic stabilization with mechanical cardiac support is sometimes used to prevent hemodynamic instability.5,6,15
The IABP was, until recently, the only percutaneous
device available during these high-risk procedures and for
patients in CS. However, IABP support has not been
shown to decrease infarct size or improve clinical
outcome.16,17 This may be due to its suboptimal improvement in cardiac support.18 Furthermore, despite being

placed through a 7F or 8F sheath, IABP catheters resulted
in a 4.3% to 5.9% rate of peripheral ischemic complications
requiring in-hospital intervention, with an incidence of
major limb ischemia in 0.9% to 2%.16,19-21 A study from
the University of Michigan reported the need for vascular
repair after IABP placement was 14%, with a 2% amputation rate.20
P-LVADs were developed to provide quick cardiac support in patients with CS or those undergoing high-risk interventional cardiac procedures. Currently available P-LVADs
include the TandemHeart system (CardiacAssist Inc, Pittsburgh, Pa) and the Impella system. They can be inserted
quickly and are less invasive than surgically implanted
LVAD for unstable patients in CS.22 In the high-risk percutaneous Coronary Intervention Study, a trend for improved
outcomes was observed using Impella 2.5 support. Major
adverse events were observed in 40.6% vs 49.3% in the
intent-to-treat population (P ¼ .066) and 40.0% vs 51.0%
in the per-protocol population (P ¼ .023).23
Our study reveals that when the Impella device was
used, vascular complications occurred in 17% of patients,
with acute limb ischemia developing in 12% and limb
loss in 4%. Our rate of hematoma (2%) is probably
under-reported. Ferreiros et al24 reported an 11.1%
vascular complications rate after Impella P-LVAD placement and a 3.7% need for vascular surgery. In the updated
USpella registry, O’Neill et al25 reported a 9.7% vascular
complications rate and a 3.9 % acute limb ischemia rate.
In the EUROSHOCK registry, 4.2% of patients required
vascular surgery.26 The Europella registry included 144
consecutive patients, and rates of vascular complications
were 4.0% at 30 days.8 Kovacic et al27 reported an 8%
vascular complications rate, mostly access-site hematomas. Burzotta et al15 reported no access-site complications. O’Neill et al24 noted that the rate of vascular
operations in the Impella 2.5 arm was no different than
that of the IABP arm (but they did not quote the limb
ischemia rate) and concluded that there was no difference
associated with the use of the larger sheath. Pershad
et al28 noted a 6% vascular complications for patients in
the PROTECT II Trial (Table VI).
In our study, vascular complications were more common in women. This is probably related to the increased
incidence of vascular complications in patients with smaller
arteries.29,30 None of the vascular complications in this study
were attributed to thromboembolic events, and all
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Fig 3. Kaplan-Meier survival curves stratiﬁed by vascular complication status, along with the log-rank P value testing for differences
in strata. The gray line indicates where the standard error is >10%.

Table VI. Major studies listing vascular complications
First author
Pershad28
Kovacic26
Sjauw8
O’Neill27
Ferreiro23
O’Neill24
Lauten25
Current study

Vascular complication rate, %
6
8
4
1
11
10
4
17

originated from injury to the artery or occlusion from the
large cannula. Patients in shock and on inotropic support
also showed a signiﬁcantly higher incidence of limb
ischemia, probably because they were hypoperfused to begin
with, and as may be expected, the Impella device was placed
for a longer time. In addition, the urgent insertion of the
Impella may predispose to vascular complications.
There is a high prevalence of PAD in the elderly
patients who constitute most of the patients with coronary
artery disease.31 The incidence of hospital and long-term
mortality after percutaneous coronary procedures is known
to be signiﬁcantly greater in patients with PAD.32,33 PAD
was noted in up to 32% of patients who presented with
CS and needed P-LVAD support.25 The documentation
of PAD is important in evaluating the safety of largesheath arterial access. The documented rate of PAD in
our study was only 7%. A much higher rate of anatomic
PAD probably existed in our patients.
Adequacy of vascular access was not routinely assessed
with computed tomography. Obviously, it is not practical
or even possible in emergent cases. For elective procedures,
there were no vascular complications, implying that studying the patient’s femoral arteries with prior angiography
before the placement of the Impella was adequate.
In this study, as expected, patients with vascular complications had a longer hospital stay. There was also a trend

in patients with vascular complications to accept hospice
care and withdrawal of cardiopulmonary support. It seems
that the addition of vascular complications may prompt a
critical reassessment of the advisability of extreme measures
for these profoundly ill patients by family members and
may promote the acceptance of end-of-life care. We found,
however, that vascular complications did not signiﬁcantly
affect the 30-day mortality in this very sick patient population. However, one cannot assume that vascular complications would not be linked to poorer survival in a lower-risk
population. Three patients (25%) in the group with acute
limb ischemia survived with a viable extremity, and patients
who developed acute limb ischemia had a 66% mortality
rate. This suggests that heroic limb salvage measures may
not be an appropriate path in this very sick group of
patients with very limited survival.
Reducing CFA cannulation complications in P-LVAD
placements should be an objective in heart failure centers.
In 2014 Abiomed introduced a “peel-away” sheath that
is removed after the device is inserted and may allow for
better distal perfusion and fewer vascular complications.
Ultrasound-guided femoral artery access may help in optimizing femoral access and should be used in difﬁcult cases.
CONCLUSIONS
Potentially devastating vascular complications occur in
this very sick population in association with the Impella
device. Vascular complications were more frequent in
women (likely due to smaller vessel size) and in emergent
procedures (likely due to the presence of shock and inotropes
predisposing to limb ischemia). Patients who developed
acute limb ischemia had a 66% in-hospital mortality rate.
Although vascular complications after P-LVAD placement will continue to occur, we believe that decreasing
sheath sizes, better screening for PAD and small vessel
size, appropriate access site selection, and increased operator experience will lower complication rates in the future.
The interventional cardiologist must be able to recognize
factors that may lead to potential vascular complications.
In addition, speciﬁc access-site complications (eg, bleeding
and acute limb ischemia) should be accurately reported so
that interested parties can understand which issues have
improved and which remain problems as technology
advances. Heroic limb salvage measures may not be an
appropriate path in this very sick group of patients with
very limited survival.
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